Jan van Breemen Research Institute/Reade, Amsterdam, The Netherlands.
Curr Opin Rheumatol. 2012 May;24(3):306-11. doi: 10.1097/BOR.0b013e3283521c4e.
To give an overview of the current knowledge on assay techniques and clinical implications of immunogenicity of biological therapeutics.
Assay techniques for the measurement of immunogenicity have improved, expanding the understanding of the immune response against biological therapeutics. Knowledge on the clinical effect of immunogenicity enables the treatment of patients in a targeted fashion, as a step towards personalized medicine.
Biological medications are able to induce an antidrug immune response. Immunogenicity impairs clinical response and is associated with adverse events. Several confounding factors influence the measurement of immunogenicity, including drug interference and background problems. Concomitant administration of methotrexate lowers the frequency and amount of antibodies formed, whereby the efficacy of biologicals is improved. Algorithms for therapeutic drug monitoring could aid in adapting treatment strategies in a controlled setting.
介绍生物治疗药物免疫原性的检测技术及临床意义的最新进展。
免疫原性检测技术的改进提高了我们对生物治疗药物的免疫反应的认识。免疫原性的临床意义知识使我们能够针对患者进行靶向治疗，朝着个性化医疗迈出了一步。
生物药物能够诱导抗药物免疫反应。免疫原性会损害临床反应，并与不良反应相关。有几个混杂因素会影响免疫原性的检测，包括药物干扰和背景问题。甲氨蝶呤的同时给药降低了抗体形成的频率和数量，从而提高了生物制剂的疗效。治疗药物监测的算法可以帮助在控制环境中调整治疗策略。
